Bioheart, Inc. Announces Positive Preliminary Data From Phase I Angel Trial

Bioheart, Inc. , a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage, announced today preliminary data from its phase I ANGEL Trial.

http://www.biospace.com/news_story.aspx?StoryID=310049&full=1